• The multinational biopharma company, which previously used a series of on-premise point solutions, will implement LifeSphere Safety due to the platform’s AI-based innovation and modern multi-tenant cloud delivery.

• The organization expects enhanced compliance and quality with end-to-end case management, along with proactive surveillance afforded via next-gen technologies.

• Leveraging LifeSphere NavaX, the company will unlock GenAI functionality, bringing comprehensive efficiency gains across end-to-end pharmacovigilance (PV) processes.

• ArisGlobal’s Transformation Services will be leveraged to adopt the modern platform and support organizational change management across global safety business and IT functions, including Japan.

Boston, Massachusetts, USA – December 4, 2024 – ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced that one of the Top 15 multinational biopharma companies has chosen LifeSphere® as its end-to-end R&D Safety platform.

Continuing their track record of bringing cutting-edge medicines to market quickly and maintaining the highest levels of safety compliance, the organization is actively seeking to harness the capabilities of advanced AI-powered technologies across all facets of Safety operations. At the forefront of innovation, they have leveraged basic automation in transactional activities of case intake and processing and are now looking to leverage new technologies to conduct proactive literature surveillance and signalling.

To meet these goals, the company will deploy the full LifeSphere Safety product suite, which is designed to offer advanced intake, literature intelligence, automated case processing, reporting, and signal management across global PV operations. They will also leverage LifeSphere NavaX to unlock Generative AI functionality to enhance their safety processes, with initial applications focused on Dynamic Data Extraction (DDE) and Narrative Generation for case intake, ensuring greater efficiency and accuracy.

Moving to the LifeSphere Safety platform, the organization has deployed an internal organizational readiness and change management plan. Operating in more than 100 countries, it’s critical for teams to understand and adopt the technology. As such, they will leverage ArisGlobal’s Consulting Services team to ensure seamless integration of LifeSphere across their global teams.

Ann-Marie Orange, CIO and Global Head of R&D for ArisGlobal, shares:

“This Top 15 pharma company is one of the world’s most innovative organizations, and their commitment to leveraging new technologies to enhance their safety processes – ultimately impacting patients around the world – is motivating for all of us at ArisGlobal. Other industries are reaping benefits of advanced automation, GenAI, and Large Language Models (LLMs), and it’s rewarding to partner with a leader like this to chart what’s next for Life Sciences. We are looking forward to many years of success and collaboration.”

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn. www.arisglobal.com.